PraxbindTM India PMS Program

NCT03359889 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 5

Last updated 2023-08-25

Study results available
· View outcomes & findings →

Summary

This program will be initiated after the commercial availability of PraxbindTM in India. It will include patients administered with PraxbindTM into the surveillance program after commercial availability in 2 years at selected centres approved by the regulatory authority.

Conditions

  • Thromboembolism

Interventions

DRUG

PraxbindTM

Drug

Sponsors & Collaborators

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-26
Primary Completion
2020-01-13
Completion
2020-01-13
FDA Drug
Yes

Countries

  • India

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03359889 on ClinicalTrials.gov